SAGIMET BIOSCIENCES INC

Inside Sagimet’s FASN‑inhibitor pipeline, a senior executive’s large share buy signals confidence ahead of Phase II data; learn why this biotech’s early safety profile and potential oncology breakthroughs could drive future upside.

Insider buying surges for SAGIMET as Kemble George purchases 20,206 shares at $6.36, reflecting confidence amid an 8.68% price jump and strong sentiment.